NEOG Quote, Financials, Valuation and Earnings

Baxter International has a net margin of -4.96% compared to Neogen's net margin of 4.8%. Neogen's return on equity of -16.44% beat Baxter International's return on equity of -7.38%.

Neogen has a consensus price target of $7.50, signalling upside risk potential of 34.41%. On the other hand Baxter International has an analysts' consensus of $38.09 which suggests that it could grow by 28.26%. Given that Neogen has higher upside potential than Baxter International, analysts believe Neogen is more attractive than Baxter International.

Neogen has a beta of 1.771, which suggesting that the stock is 77.099% more volatile than S&P 500. In comparison Baxter International has a beta of 0.610, suggesting its less volatile than the S&P 500 by 38.958%.

Neogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 2.69% to investors and pays a quarterly dividend of $0.17 per share. Neogen pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

Neogen quarterly revenues are $221M, which are smaller than Baxter International quarterly revenues of $2.6B. Neogen's net income of -$11M is lower than Baxter International's net income of $126M. Notably, Neogen's price-to-earnings ratio is 2,124.15x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen is 1.34x versus 1.28x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of -4.96% compared to Neogen's net margin of 14.45%. Neogen's return on equity of -16.44% beat Boston Scientific's return on equity of 9.57%.

Neogen has a consensus price target of $7.50, signalling upside risk potential of 34.41%. On the other hand Boston Scientific has an analysts' consensus of $117.45 which suggests that it could grow by 13.09%. Given that Neogen has higher upside potential than Boston Scientific, analysts believe Neogen is more attractive than Boston Scientific.

Neogen has a beta of 1.771, which suggesting that the stock is 77.099% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.134%.

Neogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Neogen quarterly revenues are $221M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Neogen's net income of -$11M is lower than Boston Scientific's net income of $674M. Notably, Neogen's price-to-earnings ratio is 2,124.15x while Boston Scientific's PE ratio is 75.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen is 1.34x versus 8.81x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Microbot Medical has a net margin of -4.96% compared to Neogen's net margin of --. Neogen's return on equity of -16.44% beat Microbot Medical's return on equity of --.

Neogen has a consensus price target of $7.50, signalling upside risk potential of 34.41%. On the other hand Microbot Medical has an analysts' consensus of $9.00 which suggests that it could grow by 240.91%. Given that Microbot Medical has higher upside potential than Neogen, analysts believe Microbot Medical is more attractive than Neogen.

Neogen has a beta of 1.771, which suggesting that the stock is 77.099% more volatile than S&P 500. In comparison Microbot Medical has a beta of 1.127, suggesting its more volatile than the S&P 500 by 12.737%.

Neogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbot Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neogen pays -- of its earnings as a dividend. Microbot Medical pays out -- of its earnings as a dividend.

Neogen quarterly revenues are $221M, which are larger than Microbot Medical quarterly revenues of --. Neogen's net income of -$11M is lower than Microbot Medical's net income of -$2.6M. Notably, Neogen's price-to-earnings ratio is 2,124.15x while Microbot Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen is 1.34x versus -- for Microbot Medical. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of -4.96% compared to Neogen's net margin of 11.15%. Neogen's return on equity of -16.44% beat Stryker's return on equity of 14.2%.

Neogen has a consensus price target of $7.50, signalling upside risk potential of 34.41%. On the other hand Stryker has an analysts' consensus of $422.35 which suggests that it could grow by 6.99%. Given that Neogen has higher upside potential than Stryker, analysts believe Neogen is more attractive than Stryker.

Neogen has a beta of 1.771, which suggesting that the stock is 77.099% more volatile than S&P 500. In comparison Stryker has a beta of 0.915, suggesting its less volatile than the S&P 500 by 8.528%.

Neogen has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.84% to investors and pays a quarterly dividend of $0.84 per share. Neogen pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Neogen quarterly revenues are $221M, which are smaller than Stryker quarterly revenues of $5.9B. Neogen's net income of -$11M is lower than Stryker's net income of $654M. Notably, Neogen's price-to-earnings ratio is 2,124.15x while Stryker's PE ratio is 53.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neogen is 1.34x versus 6.56x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.